Certara launches Cardiac Safety Simulator to determine arrhythmia risk for drug candidates

Based on an in-silico model of human ventricular heart cells, Certara’s Cardiac Safety Simulator (CSS) helps sponsors to assess arrhythmia risk before a new drug candidate enters clinical trials and determine safe drug doses for specific patient populations.

Register for free to listen to this article
Listen with Speechify
0:00
5:00

Certara
 
Based on an in-silicomodel of human ventricular heart cells, Certara's Cardiac Safety Simulator(CSS) helps sponsors to assess arrhythmia risk before a new drug candidateenters clinical trials and determine safe drug doses for specific patientpopulations.
 
Certara
 


Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

March 2024 Issue Front Cover

Latest Issue  

• Volume 20 • Issue 2 • March 2024

March 2024

March 2024 Issue